Sood, Shih, Van Nuys and Goldman’s Study Details the Flow of Funds in Pharma’s Distribution System

In the latest post on the the IVI-sponsored Health Affairs blog series, Neeraj Sood, Tiffany Shih, Karen Van Nuys and Dana Goldman present the findings of their study examining the flow of funds in the pharmaceutical distribution system, suggesting that greater transparency and granularity would be beneficial in the reporting of financials from all sectors. [...]

2017-07-14T05:22:43-04:00June 13th, 2017|Viewpoints|

Grabowski and Manning Respond to a Recent Post by Yu, Helms, and Bach

In a post on the the IVI-sponsored Health Affairs blog series, Henry Grabowski and Richard Manning offer a rebuttal to a recent Health Affairs blog commentary by Nancy Yu, Zachary Helms, and Peter Bach on the subject of drug pricing. In their rebuttal, Grabowski and Manning caution that the premise of the earlier blog post [...]

2017-07-14T05:22:51-04:00June 2nd, 2017|Viewpoints|

Carrier and Shadowen Propose Fixes for Pharma “Product Hopping”

In a recent post on the IVI-sponsored Health Affairs blog series, Michael Carrier and Steve Shadowen examine the practice of "product hopping," in which drug manufacturers can delay a generic introduction through product reformulation. In addition to presenting some of the prevailing issues before the courts, the authors also propose a new framework to keep the [...]

2017-07-14T05:23:04-04:00June 1st, 2017|Viewpoints|

Manolis, Good and Shrank Address Abuse-Deterrent Opioids

In the latest post on the IVI-sponsored Health Affairs blog series, Chronis Manolis, C. Bernie Good and William Shrank discuss current approaches to curbing rampant opioid abuse, including the mandating of coverage for abuse-deterrent opioids. The authors make the case that this tactic would be non-effective, costly and would distract from arriving at more comprehensive solutions [...]

2017-07-14T05:23:12-04:00May 26th, 2017|Viewpoints|

What Matters Most to Patients

In a post on the IVI-sponsored Health Affairs blog series,Josh Seidman, Margaret Anderson, Domitilla Masi, Melea Atkins and Maureen Japha examine the role of patient perspectives in assessing value in healthcare, focusing on the Avalere-FasterCures Patient-Perspective Value Framework as an example of progress toward a more patient-centered approach to value assessment. Read the full article [...]

2017-07-14T05:23:40-04:00May 23rd, 2017|Viewpoints|

Examining Policies to Promote Development of Antimicrobial Drugs

In the latest post on the IVI-sponsored Health Affairs featured blog series, Seth Seabury and Neeraj Sood examine the challenges to addressing the significant threat that antimicrobial resistant infections pose to human health. In their commentary, Seabury and Sood focus on three of the most commonly proposed policies to promote the development of new antimicrobials: market [...]

2017-07-14T05:23:48-04:00May 18th, 2017|Viewpoints|

Review of Key Provisions of FDA’s User Fee Reauthorization Bill

In the latest post on the IVI-sponsored Health Affairs featured blog series, Rachel Sachs addresses key provisions of the FDA's proposed user fee reauthorization bill. Included in her assessment are details of new language changes and amendments added to the bill, as well as a look forward to potential obstacles to the bill's final passage. Read [...]

2017-07-14T05:24:06-04:00May 15th, 2017|Viewpoints|

Hwang and Kesselheim Analyze the Impact of Taxing Drug Price Spikes

In a recent post on the IVI-sponsored Health Affairs featured blog series,Thomas Hwang and Aaron Kesselheim examine proposed new legislation taxing manufacturers of pharmaceuticals with medications exhibiting significant pricing spikes. Hwang and Kesselheim break down the criteria for the tax, and also offer some insight into potential policy implications. Read the full article here. About the Health [...]

2017-07-14T05:24:15-04:00May 12th, 2017|Viewpoints|

Lakdawalla and Balch Make the Case for Patient-Centered Assessment of Value

In a recent post on the IVI-sponsored Health Affairs featured blog series, IVI’s Darius Lakdawalla and Alan Balch stress the importance of incorporating the patient perspective into value assessments in healthcare, and of developing tools to help patients make value-based decisions in the marketplace. The Balch and Lakdawalla piece reflects IVI’s view that value in healthcare rests [...]

2017-07-14T05:24:44-04:00May 8th, 2017|Viewpoints|

Orphan Drugs, Pursuing Value, and Avoiding Unintended Effects of Regulations

In a recent post on the IVI-sponsored Health Affairs featured blog series, Joshua Liao and Mark Pauly examine the role of government regulation of orphan drugs in rising drug prices, providing some specific examples and how they relate to the provisions of the Orphan Drug Act. Liao and Pauly also present some potential solutions to the problem, including [...]

2017-07-14T05:24:58-04:00May 4th, 2017|Viewpoints|
Go to Top